Abstract Learning Objectives Discuss the response rate, median PFS, and adverse events
associated with sorafenib therapy for metastatic thyroid cancers. Background. Sorafenib was …

The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs)
has undergone major advancements in the last decade, causing a paradigm shift in the …

Importance Anaplastic thyroid carcinoma (ATC) historically has a 4-month median overall
survival (OS) from time of diagnosis, with disease-specific mortality approaching 100%. The …

Immune checkpoint inhibitors (anti–cytotoxic T-lymphocyte antigen 4 and anti programmed
cell death 1/programmed cell death 1 ligand antibodies) have shown impressive clinical …

The deadliest anaplastic thyroid cancer (ATC) often transforms from indolent differentiated
thyroid cancer (DTC); however, the complex intratumor transformation process is poorly …

Background: Although immune-related thyroiditis (irT) with immune checkpoint inhibitors
(ICI) is a common consequence, its natural course and management recommendations are …

Background: When achieved, complete surgical resection improves outcomes in anaplastic
thyroid carcinoma (ATC). However, most ATC patients present with advanced inoperable …

Background Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer.
Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC …

Background Current treatment guidelines for immune-mediated colitis (IMC) recommend 4
to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy …

Anaplastic thyroid cancer (ATC) is a devastating disease with a dismal prognosis. Patients
who have disease confined to the thyroid and who are able to undergo complete surgery …